No Data
No Data
S&P 500 Futures Climb In Premarket Trading; Neurocrine Biosciences, Equitable Holdings Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. With U.S. stock markets set to open in two hours, Neurocrine Biosciences Inc. (NBIX) was up 8.8% in
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 62.1%
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper Sandler
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper
Roivant Sciences Is Maintained at Overweight by Piper Sandler
Roivant Sciences Is Maintained at Overweight by Piper
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $22
Piper Sandler analyst Allison Bratzel maintains $Roivant Sciences(ROIV.US)$ with a buy rating, and adjusts the target price from $20 to $22.According to TipRanks data, the analyst has a success rate
Express News | Roivant Sciences Ltd : Piper Sandler Raises Target Price to $22 From $20